The Thrombopoietin Receptor pipeline drugs market research report outlays comprehensive information on the Thrombopoietin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Thrombopoietin Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Hematological Disorders, Toxicology, and Oncology which include the indications Thrombocytopenia, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), and Myelodysplastic Syndrome. It also reviews key players involved in Thrombopoietin Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Thrombopoietin Receptor pipeline targets constitutes close to 18 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 6, 1, 3, 3, and 1 respectively. Similarly, the universities portfolio in Phase II, and Phase I comprises 1, and 1 molecule.
Thrombopoietin Receptor overview
Thrombopoietin receptor (MPL) is a receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. It represent a regulatory molecule specific for TPO-R-dependent immune responses.
For a complete picture of Thrombopoietin Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.